Development and validation of a simple correction method for the measurement of neuron-specific enolase in hemolyzed serum samples

Lauwers, Maïlis; Frikha, Amal; Fage, David; Duterme, Cécile; Vos, Nathalie De; Cotton, Frédéric; Wolff, Fleur

doi:10.1080/00365513.2021.2009021

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it is worth noting that NSE is also present in red blood cells and platelets. Therefore, it is necessary to exclude hemolytic samples when measuring NSE in plasma or serum to avoid NSE interference results from other sources ( 40 ). Further studies are required to find the optimal combination of biomarkers for diagnostic and prognostic purposes.…”

Section: Discussionmentioning

confidence: 99%

Role of serum neuron-specific enolase levels in the early diagnosis and prognosis of sepsis-associated encephalopathy: a systematic review and meta-analysis

Pei,

Yang,

Zhang

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

BackgroundSepsis-associated encephalopathy (SAE) is one of the most ubiquitous complications of sepsis and is characterized by cognitive impairment, poor prognosis, and a lack of uniform clinical diagnostic criteria. Therefore, this study investigated the early diagnostic and prognostic value of serum neuron-specific enolase (NSE) in SAE.MethodsThis systematic review and meta-analysis systematically searched for clinical trials with serum NSE information in patients with sepsis in the PubMed, Web of Science, Embase, and Cochrane databases from their inception to April 10, 2023. Included studies were assessed for quality and risk of bias using The Quality Assessment of Diagnostic Accuracy-2 tool. The meta-analysis of the included studies was performed using Stata 17.0 and Review Manager version 5.4.FindingsEleven studies were included in this meta-analysis involving 1259 serum samples from 947 patients with sepsis. Our results showed that the serum NSE levels of patients with SAE were higher than those of the non-encephalopathy sepsis group (mean deviation, MD,12.39[95% CI 8.27–16.50, Z = 5.9, p < 0.00001]), and the serum NSE levels of patients with sepsis who died were higher than those of survivors (MD,4.17[95% CI 2.66–5.68, Z = 5.41, p < 0.00001]).ConclusionElevated serum NSE levels in patients with sepsis are associated with the early diagnosis of SAE and mortality; therefore, serum NSE probably is a valid biomarker for the early diagnosis and prognosis of patients with SAE.Systematic review registrationThis study was registered in PROSPERO, CRD42023433111.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of serum neuron-specific enolase levels in the early diagnosis and prognosis of sepsis-associated encephalopathy: a systematic review and meta-analysis

Pei,

Yang,

Zhang

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Vertebrates possess 3 isozymes of enolase, expressed by different genes: enolase-α is ubiquitous; enolase-β is muscle-specific and enolase-γ (NSE) is neuron-specific ( Isgrò et al, 2015 ). Since NSE is also present in erythrocytes and thrombocytes, either hemolytic samples must be excluded or a NSE correction method has to be employed for hemolyzed samples ( Lauwers et al, 2022 ). Since practices to report the hemolysis index are poorly standardized across different manufacturers of assays and laboratory equipment ( Simundic et al, 2020 ), we suggest to use only samples with no detectable hemolysis for NSE determination in plasma or serum.…”

Section: Indicators Of Sepsis and Septic Encephalopathymentioning

confidence: 99%

Septic encephalopathy in the elderly – biomarkers of potential clinical utility

Schütze,

Drevets,

Tauber

et al. 2023

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Next to acute sickness behavior, septic encephalopathy is the most frequent involvement of the brain during infection. It is characterized by a cross-talk of pro-inflammatory cells across the blood–brain barrier, by microglial activation and leukocyte migration, but not by the entry of infecting organisms into the brain tissue. Septic encephalopathy is very frequent in older persons because of their limited cognitive reserve. The predominant clinical manifestation is delirium, whereas focal neurological signs and symptoms are absent. Electroencephalography is a very sensitive method to detect functional abnormalities, but these abnormalities are not specific for septic encephalopathy and of limited prognostic value. Routine cerebral imaging by computer tomography usually fails to visualize the subtle abnormalities produced by septic involvement of the brain. Magnetic resonance imaging is by far more sensitive to detect vasogenic edema, diffuse axonal injury or small ischemic lesions. Routine laboratory parameters most suitable to monitor sepsis, but not specific for septic encephalopathy, are C-reactive protein and procalcitonin. The additional measurement of interleukin (IL)-6, IL-8, IL-10 and tumor necrosis factor-α increases the accuracy to predict delirium and an unfavorable outcome. The most promising laboratory parameters to quantify neuronal and axonal injury caused by septic encephalopathy are neurofilament light chains (NfL) and S100B protein. Neuron-specific enolase (NSE) plasma concentrations are strongly influenced by hemolysis. We propose to determine NSE only in non-hemolytic plasma or serum samples for the estimation of outcome in septic encephalopathy.

show abstract

Development and validation of a simple correction method for the measurement of neuron-specific enolase in hemolyzed serum samples

Cited by 2 publications

References 13 publications

Role of serum neuron-specific enolase levels in the early diagnosis and prognosis of sepsis-associated encephalopathy: a systematic review and meta-analysis

Role of serum neuron-specific enolase levels in the early diagnosis and prognosis of sepsis-associated encephalopathy: a systematic review and meta-analysis

Septic encephalopathy in the elderly – biomarkers of potential clinical utility

Contact Info

Product

Resources

About